Demand is soaring and can be met There is significant demand for GLP-1s
UHCs typical prior authorization requirements for Wegovy and Zepbound include: BMI documentation A documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea Comorbidity evidence Clinical records documenting the specific comorbidities that support the medical necessity of treatment Supervised weight management history Evidence of participation in a structured weight management program, which may include diet, exercise, and behavioral counseling, typically for 3 to 6 months prior to the request Prescriber qualifications The prescriber must be a physician, nurse practitioner, or physician assistant with appropriate prescribing authority UHC reviews prior authorizations against specific clinical policy bulletins
Stability is also influenced by temperature variations
Additionally, your doctor may recommend specific doses of each medication that work well together
Supports Exercise PerformanceL-carnitine and L-tyrosine contribute to increased endurance, fat utilization, and recovery during physical activity
"Lilly must divest Sentinel products after FTC nod on Novartis deal"